Clinical Trials › NCT04544449

Active, Not RecruitingPhase 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

Sponsored by Hoffmann-La Roche

Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov
985
Target enrollment
24
U.S. states
Oct 2020
Start date
Jul 2027
Expected completion
Interventions / Treatments
FenebrutinibOcrelizumabPlacebo matched to ocrelizumabPlacebo matched to fenebrutinib
Conditions studied
Multiple Sclerosis, Primary Progressive
Where this trial is running (43 sites)
New Jersey5 sites
Hackensack · Livingston · Neptune City · +2 more
New York5 sites
Amherst · New York · Rochester · +2 more
California3 sites
Berkeley · Fullerton · Sunnyvale
Florida3 sites
Maitland · Orlando · Tampa
Ohio3 sites
Centerville · Cincinnati · Columbus
Tennessee3 sites
Cordova · Knoxville · Nashville
North Carolina2 sites
Charlotte · Raleigh
Texas2 sites
Houston · Sherman
Washington2 sites
Kirkland · Seattle
Alabama1 site
Homewood
Colorado1 site
Aurora
Connecticut1 site
Fairfield
District of Columbia1 site
Washington D.C.
Indiana1 site
Indianapolis
Kansas1 site
Kansas City
Maryland1 site
Baltimore
Massachusetts1 site
Wellesley
Michigan1 site
Detroit
Minnesota1 site
Golden Valley
Missouri1 site
St Louis
Nevada1 site
Las Vegas
Oregon1 site
Portland
West Virginia1 site
Morgantown
Wisconsin1 site
Milwaukee
Participating MS centers on MS Buddy (31)
MS centers in New Jersey

Compare treatment centers near a trial site — patient experience, providers, and care ratings.

View New Jersey centers
More Phase 3 trials
Browse all Phase 3 MS trials

Check out the MS Buddy App

Track symptoms, monitor wellness, and stay on top of your MS care. It's free, no ads. How? It's made and supported by MS patients who get their ideas from other MS patients.

Download on the App StoreGet it on Google Play